144 related articles for article (PubMed ID: 33112798)
1. Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Lee EJ; Yoon JS
J Mol Endocrinol; 2021 Jan; 66(1):71-81. PubMed ID: 33112798
[TBL] [Abstract][Full Text] [Related]
2. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
[TBL] [Abstract][Full Text] [Related]
3. Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy.
Ko J; Kim JY; Kim JW; Yoon JS
Endocr J; 2020 Apr; 67(4):439-447. PubMed ID: 31941844
[TBL] [Abstract][Full Text] [Related]
4. Neferine suppresses autophagy-induced inflammation, oxidative stress and adipocyte differentiation in Graves' orbitopathy.
Li H; Gao L; Min J; Yang Y; Zhang R
J Cell Mol Med; 2021 Feb; 25(4):1949-1957. PubMed ID: 33443817
[TBL] [Abstract][Full Text] [Related]
5. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
[TBL] [Abstract][Full Text] [Related]
6. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
[TBL] [Abstract][Full Text] [Related]
8. The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy.
Kim SE; Lee JH; Chae MK; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):301-11. PubMed ID: 26830367
[TBL] [Abstract][Full Text] [Related]
9. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy.
Kim BR; Kim J; Lee JE; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):39. PubMed ID: 32196098
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathy.
Ko J; Kim JY; Kim BR; Lee EJ; Kikkawa DO; Yoon JS
Mol Cell Endocrinol; 2021 Aug; 534():111363. PubMed ID: 34116129
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of Curcumin, a Plant Polyphenol Extracted From Curcuma longae, in Fibroblasts From Patients With Graves' Orbitopathy.
Lee JS; Kim J; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4129-4140. PubMed ID: 31593984
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effect of Resveratrol on Oxidative Stress in Graves' Orbitopathy Orbital Fibroblasts.
Kim CY; Lee HJ; Chae MK; Byun JW; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6352-61. PubMed ID: 26436888
[TBL] [Abstract][Full Text] [Related]
14. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee JS; Chae MK; Kikkawa DO; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):51. PubMed ID: 32735324
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
16. Polydatin attenuates orbital oxidative stress in Graves' orbitopathy through the NRF2 pathway.
Li H; Min J; Chen Y; Li H; Zhang Y
Chem Biol Interact; 2020 Jan; 315():108894. PubMed ID: 31705858
[TBL] [Abstract][Full Text] [Related]
17. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
18. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee CE; Choi SH; Yoon JS
Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of Protocatechuic Aldehyde in an In Vitro Model of Graves' Orbitopathy.
Byun JW; Hwang S; Kang CW; Kim JH; Chae MK; Yoon JS; Lee EJ
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4055-62. PubMed ID: 27494347
[TBL] [Abstract][Full Text] [Related]
20. Role of Inositol-Requiring Enzyme 1 and Autophagy in the Pro-Fibrotic Mechanism Underlying Graves' Orbitopathy.
Lee CE; Kim JY; Yoon JS; Ko J
Yonsei Med J; 2024 Jul; 65(7):397-405. PubMed ID: 38910302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]